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The consequences of alcohol use disorders (AUDs)
are devastating to individuals and society, yet few
treatments are currently available. To identify genes
regulating the behavioral effects of ethanol, we con-
ducted a genetic screen in Drosophila and identified
amutant,happyhour (hppy), due to its increasedresis-
tance to the sedative effects of ethanol. Hppy protein
shows strong homology to mammalian Ste20 family
kinases of the GCK-1 subfamily. Genetic and
biochemical experiments revealed that the epidermal
growth factor (EGF)-signaling pathway regulates
ethanol sensitivity in Drosophila and that Hppy func-
tions as an inhibitor of the pathway. Acute pharmaco-
logical inhibition of the EGF receptor (EGFR) in adult
animals altered acute ethanol sensitivity in both flies
and mice and reduced ethanol consumption in
a preclinical rat model of alcoholism. Inhibitors of the
EGFR or components of its signaling pathway are
thus potential pharmacotherapies for AUDs.
INTRODUCTION
Alcohol (ethanol) is one of the most popularly consumed and
abused drugs in the world. Its pleasurable and disinhibiting
effects have been enjoyed by humankind for thousands of years.
For some, however, alcohol consumption leads to addiction,
a devastating illness with enormous medical and societal costs.
A better understanding of the genetic and environmental factors
that contribute to thedevelopment of alcohol usedisorders (AUD)
would, therefore, provide considerable benefits to those who
suffer its consequences and to society. Although the cognitive
and behavioral changes associated with alcohol consumption
are familiar to many, our knowledge concerning themechanisms
through which ethanol acts in the central nervous system to
produce these effects is still far from complete. Rather than
acting on a single molecular target, ethanol affects the functionof multiple targets—most commonly, voltage- and ligand-gated
ion channels (Diamond and Gordon, 1997; Lovinger, 1997).
Studies of genetically engineered mice have provided further
insight into molecules that regulate the behavioral response to
ethanol in vivo, demonstrating roles for serotonin, dopamine,
and cannabinoid systems, as well as several signal transduction
pathways (Crabbe et al., 2006).
Family, adoption, and twin studies strongly support a genetic
component to alcoholism, although identifying specific genes
underlying alcoholism has proved difficult (Reich et al., 1999;
Dick et al., 2004; Edenberg et al., 2004; Schuckit et al., 2004).
Human studies also indicate that the level of response to intox-
icating doses of ethanol acts as a predictor of future alcoholism,
with a lower initial response correlated with increased risk
(Schuckit, 1994; Schuckit and Smith, 1996). Thus, the identifica-
tion of genes and pathways mediating acute responses to
ethanol promises to offer insight into the genetic factors contrib-
uting to the much more complex process of addiction.
The fruit fly, Drosophila melanogaster, has proven to be
a useful model system in which to study the genes and pathways
that mediate acute and chronic behavioral responses to ethanol
(Guarnieri and Heberlein, 2003). Upon acute ethanol exposure,
flies exhibit behaviors similar to those observed in mammals:
low ethanol doses result in hyperactivity, whereas higher doses
cause decreased activity and eventual loss of postural control
and sedation (Singh and Heberlein, 2000; Wolf et al., 2002).
Unbiased genetic approaches and candidate gene analyses
have provided insight into various molecules and biochemical
pathways that regulate the ethanol response in Drosophila
(Moore et al., 1998; Park et al., 2000; Corl et al., 2005; Wen
et al., 2005; Rothenfluh et al., 2006) as well as the responsible
neuroanatomical loci (Rodan et al., 2002; Urizar et al., 2007).
Several of the molecules implicated in ethanol-related behaviors
in Drosophila, such as protein kinase A (PKA), calcium-sensitive
adenylate cyclase (Moore et al., 1998), and the fly ortholog of
neuropeptide Y, NPF (Wen et al., 2005), have been shown to
have similar roles in mammals (Thiele et al., 2000, 2002; Maas
et al., 2005), corroborating Drosophila as a valuable model.
To identify molecules and pathways regulating the behavioral
response to ethanol, we conducted a genetic screen for
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Figure 1. hppy Mutants Display Increased
Resistance to Ethanol Sedation
(A) hppy17-51 flies show increased resistance to
ethanol-induced sedation in the loss of righting
(LOR) assay, and precise excision of the P element
in hppy17-51 (exc. 3 and 16) reverted the sedation
resistance phenotype. Ethanol exposure (110/40
E/A) commenced at 0 min and was continuous
thereafter (n = 8).
(B) The median sedation time (ST50)—the time
required for half of the ethanol-exposed flies to
show LOR—was calculated by linear interpolation.
(C and D) hppyKG5537 flies also showed increased
resistance to ethanol-induced sedation. (C) Seda-
tion profiles and (D) ST50 values were calculated
for hppy17-51, control, and hppyKG5537. Error bars
represent SEM, and asterisks denote statistical
significance by one-way ANOVA followed by
post hoc Newman-Keuls testing. n = 8–12.
(E) Diagram of the hppy transcription unit, with
exons represented as boxes. M indicates the
translation start site, and an asterisk indicates
the stop codon. Blue arrows indicate regions
amplified for QPCR analysis. Structures of the
two transcripts, hppy-RA and hppy-RB, and the
insertion sites of hppy17-51 and hppyKG5537 are
diagrammed.
(F and G) Expression of hppy is reduced in hppy
mutants. RNA was isolated from whole flies and
subjected to QPCR. Similar results were obtained
with mRNA isolated from heads and bodies sepa-
rately (data not shown). Relative mRNA levels are
expressed as fold difference relative to w Berlin
(wB) control RNA. QPCR onwhole-flymRNA using
a primer/probe set recognizing both hppy-RA and
hppy-RB transcripts (F) or only the hppy-RA tran-
script (G) is shown. One-way ANOVA with post
hoc Newman-Keuls tests revealed a significant
difference between hppy17-51 and both wB and
Ctrl and between hppyKG5537 and both controls.
n = 3.
***p < 0.001.Drosophila mutants with altered sensitivity to ethanol’s sedative
effects. Here, we describe the identification and characterization
of mutants in the happyhour (hppy) gene, which exhibit a marked
resistance to ethanol-induced sedation. A series of genetic,
behavioral, and biochemical experiments suggest that hppy
modulates ethanol sedation by regulating EGFR signaling in
the nervous system. These experiments also strongly suggest
that hppy acts as an inhibitor of the EGFR pathway. Finally, acute
pharmacological inhibition of the EGFR significantly perturbed
ethanol sensitivity in both adult flies and mice and reduced
ethanol consumption in rats.
RESULTS
hppy Mutants Display Increased Resistance
to Ethanol-Induced Sedation
To identify molecules mediating the sedative effects of ethanol in
Drosophila, we screened a collection of strains carrying random
950 Cell 137, 949–960, May 29, 2009 ª2009 Elsevier Inc.insertions of the P{GawB} transposable element by using a loco-
motor tracking device (Wolf et al., 2002). When exposed to a
relatively high concentration of ethanol (see Supplemental
Experimental Procedures available online), Drosophila exhibit
a transient startle response to the smell of ethanol, followed by
a decrease in locomotor activity associated with gradual loss
of postural control and, finally, akinesis (sedation) (Wolf et al.,
2002). We isolated one mutant, line 17-51, that displayed
increased resistance to ethanol-induced sedation (Figure S1A).
Direct observation of sedation responses using a modified
loss-of-righting (LOR) assay (Rothenfluh et al., 2006) confirmed
that 17-51 flies displayed marked resistance to ethanol-induced
sedation (Figures 1A and 1B), a phenotype evident at all ethanol
concentrations tested (Figure S2). This was not simply due to
altered ethanol pharmacokinetics, as ethanol absorption was
normal in 17-51 flies (Figure S1B). In addition, 17-51 flies showed
normal locomotor behavior and negative geotaxis (Figure S3
and data not shown).
Inverse PCR and DNA sequencing analysis revealed that the
P{GawB} element in 17-51 is inserted in the gene CG7097,
affecting its expression (see below). We decided to name the
gene happyhour (hppy) because its mutation results in flies
being able to imbibe significantly more alcohol than wild-type
controls before succumbing to its sedating effects. The trans-
poson inserted in hppy17-51 is responsible for the sedation resis-
tance, as precise excisions of the element reverted the mutant
phenotype (Figures 1A and 1B). Database searches (http://
www.flybase.org) identified a second P element insertion in
CG7097, KG5537. When tested in the LOR assay, this strain,
hppyKG5537, also showed increased resistance to ethanol-
induced sedation (Figures 1C and 1D). In addition, hppy17-51
and hppyKG5537 failed to complement each other’s ethanol
sedation phenotypes (data not shown).
Molecular Characterization of the hppy Locus
and hppy Mutants
Thehppy (CG7097) locus covers48.5 kb and encodes two tran-
scripts, hppy-RA and hppy-RB (Figure 1E; http://www.flybase.
org). Both transcripts, generated by alternative splicing of the
eighth intron, share the same transcription start site, but the
longer 5.1 kb hppy-RA transcript contains an additional 800
bp in its ninth exon, not included in hppy-RB. Both hppymutants
harborP element insertions in the 50 gene region. In hppy17-51, the
transposon is inserted 10 bp upstream of the transcription start
site; the hppyKG5537 transposon is inserted in the first noncoding
exon (Figure 1E). The hppy-RA and hppy-RB transcripts are pre-
dicted to encode proteins with an N-terminal serine/threonine
kinase domain and a citron-homology domain near the C
terminus. The closest mammalian homologs of Hppy are
members of the germinal center kinase-1 (GCK-1) family of
Ste20-related kinases, including GLK (germinal center-like
kinase) and GCK itself (Dan et al., 2001; Findlay et al., 2007).
GCK-1 family members have been shown previously to act as
mitogen-activated protein kinases (MAPKs) upstream of the
Jun N-terminal kinase (JNK)-signaling pathway (Chen and Tan,
1999), although studies in Drosophila cell culture have failed to
show such a role for CG7097 (hppy) (Findlay et al., 2007).
Todetermine how thesemutations affecthppyexpression,we
measured hppy transcript levels in the mutant and control
strains by quantitative RT-PCR (QPCR). Using a primer and
probe set recognizing both hppy-RA and -RB transcripts, we
examined hppy expression in adult flies and during develop-
ment. The relative expression of hppy in the hppy17-51 and
hppyKG5537 mutants was reduced to approximately half that
of controls in adult flies (Figure 1F); relative hppy levels were
also decreased in hppy mutant flies during development
(Figure S4). A similar reduction in hppy expression was seen in
the mutants with a primer and probe set recognizing specifically
the hppy-RA transcript (Figure 1G). In summary, we have identi-
fied two mutations in the CG7097/hppy locus that share an
increased resistance to ethanol-induced sedation and show
reduced levels of hppy transcripts.
Neuronal hppy Expression Is Sufficient for Normal
Ethanol Sensitivity
To conclusively demonstrate that the increased sedation resis-
tance observed in hppy mutants was due to decreased hppyexpression, we tested rescue of the mutant phenotype by
expressing a UAS-hppy transgene in hppy mutants. We gener-
ated a UAS-hppyRB construct by inserting the hppy-RB cDNA
into the pUAST vector (see Supplemental Experimental Proce-
dures) and introduced this transgene into hppy17-51 homozygous
mutant flies. The hppy17-51 P[GAL4] insertion drives widespread
GAL4 expression in many tissues, including the central nervous
system, as visualized with a UAS-green fluorescent protein
(UAS-GFP) reporter (Figures 2A and 2B). hppy17-51 homozygous
mutant flies carrying the UAS-hppyRB1 transgene showed
increased expression of specifically hppy-RB (QPCR) (Figures
S5A and S5B). When tested in the LOR assay, these flies dis-
played normal sedation sensitivity (Figure 2C), indicating
complete rescue of the mutant phenotype by hppy-RB expres-
sion. Partial rescue was achieved with a second, more weakly
expressed insertion of UAS-hppyRB (Figures S5C and S5D).
Importantly, introduction of the UAS-hppyRB transgene into the
hppyKG5537 homozygous mutant, in which GAL4 is not ex-
pressed, did not rescue the hppyKG5537 sedation resistance
phenotype (Figure 2D). These data confirm that the reduction
in hppy expression is responsible for the resistance to ethanol-
induced sedation observed in hppy mutant flies.
To determine whether expression of hppy specifically in the
nervous systemwas sufficient to restore normal ethanol-induced
sedation to hppy mutants, we expressed the UAS-hppyRB1
transgene in neurons using the elav-GAL4c155 driver in
hppyKG5537 homozygous flies. Neuronal expression of hppy-RB
completely rescued the sedation resistance of hppyKG5537
(Figure 2E). Conversely, expressing the UAS-hppyRB1 transgene
under the control of elav-GAL4c155 in an otherwise wild-type
background caused increased sensitivity in the LOR assay
(Figure 2F). Thus, hppy functions in neurons to control ethanol-
induced sedation, and the pathway whose function is regulated
by hppy can operate bidirectionally to enhance or suppress the
response to the sedating effects of ethanol.
JNK Signaling Does Not Regulate Ethanol-Induced
Sedation
Because previous work had shown that a human homolog of
hppy, GCK, acts as a MAP4K in the JNK pathway (Pombo
et al., 1995; Dan et al., 2001), we investigated whether perturba-
tion of the JNK pathway in Drosophila would alter ethanol sensi-
tivity (Figure S6). Panneuronal expression of various transgenes
that activate or inhibit the JNK pathway did not alter ethanol
sensitivity. For example, flies expressing a constitutively acti-
vated form of the JNKK hemipterous or a dominant-negative
form of the JNK homolog basket, showed wild-type ethanol
sensitivity (Figures S6A and S6B). Similarly, neuronal manipula-
tions of the JNK pathway transcription factor dJUN, through
overexpression of wild-type or a dominant-negative form, failed
to affect ethanol-induced sedation (Figures S6C and S6D). We
also tested the effects of perturbing the p38 pathway, with
equally negative results (Figure S6E and data not shown).
EGFR/ERK Signaling Regulates Ethanol Sensitivity
Because manipulations of the JNK and p38 pathways failed to
alter ethanol sensitivity, we tested the role of the extracellular
signal-regulated protein kinase (ERK) pathway. Specifically, we
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Figure 2. Phenotypic Rescue and Overexpression of hppy
(A and B) The hppy17-51 GAL4 expression pattern is widespread in the fly CNS.
Pictured is an image of the adult brain (A) and ventral nerve cord (B) of a fly
harboring hppy17-51 and UAS-GFP.
(C) Thehppy17-51 sedation resistance canbe rescuedby expression of theUAS-
hppyRB1 transgene in the hppy17-51 homozygous mutant background. A signif-
icant difference was observed between hppy17-51/hppy17-51;UAS-hppyRB1/+
and hppy17-51/hppy17-51. ST50 of hppy17-51/hppy17-51;UAS-hppyRB1/+ was not
significantly different than control (p > 0.05) or UAS-hppyRB1/+ (p > 0.05)
(n = 8–12).
(D) Introduction of the UAS-hppyRB1 transgene into the hppyKG5537 mutant
background, which lacks GAL4 activity, did not rescue the hppyKG5537 sedation
resistance. Significant differences were observed when comparing
hppyKG5537/hppyKG5537;UAS-hppyRB1/+ with control or UAS-hppyRB1/+ flies.
ST50 of hppyKG5537/hppyKG5537;UAS-hppyRB1/+ was not significantly different
than hppyKG5537/hppyKG5537 (p > 0.05) (n = 8).
(E) Panneuronal expression of UAS-hppyRB1 under the control of the
elav-GAL4c155 driver rescued the sedation resistance of hppyKG5537 flies.
Significant differences were observed between elav-GAL4c155;hppyKG5537/952 Cell 137, 949–960, May 29, 2009 ª2009 Elsevier Inc.asked whether perturbation of the ERK pathway activated by the
EGFR affected ethanol-induced sedation by expressing various
EGFR-pathway transgenes using panneuronal drivers (elav-
GAL4c155, elav-GAL43E1). Using the ubiquitous driver Tub-
GAL4 resulted in lethality in all cases except when driving
expression of a secreted form of the EGFR ligand encoded by
the spitz (spi) gene.
Manipulations that enhanced EGFR signaling at several levels
in the pathway potently increased resistance to ethanol-induced
sedation (Figure 3). Increasing expression of an activated form of
the EGFR ligand Spitz (UAS-spiSEC) strongly increased resis-
tance to ethanol-induced sedation (Figure 3A and data not
shown). Marked resistance was also produced by neuronal over-
expression of a wild-type EGFR transgene (UAS-egfrWT, Fig-
ure 3B), a gain-of-function Raf MAP3K (data not shown), or
a constitutively active form of the ERK rolled (rl) (UAS-rlACT, Fig-
ure 3C). Conversely, inhibiting EGFR signaling resulted in the
opposite effect: enhanced sensitivity to ethanol-induced seda-
tion. For example, a mutant in rhomboid (rho), encoding
a protease that activates Spitz (Lee et al., 2001), displayed
enhanced sensitivity to ethanol-induced sedation (Figure 3D).
In this mutant, which harbors a P element insertion in the
promoter region of rho (Figure S7A), mRNA levels were reduced
to 30% of wild-type (Figure S7C). We also tested a mutant in
Star (S), which encodes a chaperone required for trafficking of
Spitz (Lee et al., 2001). Sd01624 flies, which carry a P element
insertion in the Star gene (Figure S7B) that reduces Star function
as ascertained by complementation analysis with a null allele of
Star (see Supplemental Experimental Procedures), also showed
enhanced sensitivity to ethanol-induced sedation (Figure 3E).
Finally, we utilized an RNAi transgene that targets the egfr,
UAS-egfrRNAi, which strongly reduces egfr transcript levels
when expressed with elav-GAL4c155 (Figure S7D); this also re-
sulted in increased sensitivity to ethanol-induced sedation
(Figure 3F). Taken together, our data strongly support a role for
the EGFR pathway in regulating ethanol-induced sedation in
Drosophila, where inhibition of the pathway leads to enhanced
sensitivity to ethanol-induced sedation, whereas its activation
leads to the opposite phenotype.
Hppy Is a Negative Regulator of the EGFR/ERK Pathway
Based on our observations that enhanced EGFR signaling and
reduced hppy function both led to increased ethanol resistance,
whereas reduced EGFR signaling and hppy overexpression
produced the opposite effect, we reasoned that hppymay func-
tion as an inhibitor of the EGFR pathway. To test this hypothesis,
we first resorted to the fly eye, where the developmental role of
EGFR signaling has been thoroughly studied (Dominguez et al.,
hppyKG5537;UAS-hppyRB1/+ and (1) hppyKG5537/hppyKG5537, (2) elav-
GAL4c155;hppyKG5537/hppyKG5537, and (3) hppyKG5537/hppyKG5537;UAS-
hppyRB1/+. ST50 of elav-GAL4c155; hppyKG5537/ hppyKG5537; UAS-hppyRB1/+
was not significantly different than control (p > 0.05) (n = 8).
(F) Neuronal overexpression of UAS-hppyRB1 using the elav-GAL4c155 driver
increased sensitivity to ethanol-induced sedation. Significant differences
were observed when comparing elav-GAL4c155;UAS-hppyRB1/+ with elav-
GAL4c155 or UAS-hppyRB1/+ (n = 8).
***p < 0.001, one-way ANOVA with post hoc Newman-Keuls tests. Error bars
represent SEM.
Figure 3. Activation or Inhibition of EGFR/
ERK Signaling in Neurons Alters Ethanol
Sensitivity
(A) Flies expressing a secreted form of the EGFR
ligand Spitz, UAS-spiSEC, under the control of the
panorganismal driver Tub-GAL4 were resistant to
ethanol-induced sedation. Significant differences
were observed between Tub-GAL4/+;UAS-
spiSEC/+ and Tub-GAL4/+ (**p < 0.01) as well as
between Tub-GAL4/+;UAS-spiSEC/+ and UAS-
spiSEC/+ (***p < 0.001) (n = 8).
(B) Flies overexpressing a wild-type form of the
EGFR, UAS-egfrWT, under the control of the pan-
neuronal driver elav-GAL4c155 were resistant to
ethanol-induced sedation. Significant differences
were observed between elav-GAL4c155;UAS-
egfrWT/+ and elav-GAL4c155, as well as between
elav-GAL4c155;UAS-egfrWT/+ and UAS-egfrWT/+
(***p < 0.001) (n = 8).
(C) Flies expressing a constitutively active form of
the ERK rolled, UAS-rlACT, under the control of the
panneuronal driver elav-GAL4c155 displayed
increased resistance to ethanol-induced sedation.
Significant differences were observed between
elav-GAL4c155;UAS-rlACT/+ and elav-GAL4c155
(**p < 0.01) as well as between elav-GAL4c155;
UAS-rlACT/+ and UAS-rlACT/+ (***p < 0.001)
(n = 7–8).
(D) The P element-induced loss-of-function rho
mutant, rhoA0544, displayed enhanced sensitivity
to ethanol-induced sedation (***p < 0.0001) (n = 8).
(E) The P element-induced Star mutant, Sd01624,
showed enhanced sensitivity to ethanol-induced
sedation (***p < 0.0001) (n = 8).
(F) Flies expressing RNAi against the EGFR,
UAS-egfrRNAi, under the control of the panneuronal driver elav-GAL4c155 were sensitive to ethanol-induced sedation. Significant differences were observed
between elav-GAL4c155;UAS-egfrRNAi/+ and elav-GAL4c155 (*p < 0.05) as well as between elav-GAL4c155;UAS-egfrRNAi/+ and UAS-egfrRNAi/+ (p < 0.01) (n = 12).
(A–C and F) One-way ANOVA with post hoc Newman-Keuls tests.
(D and E) Student’s unpaired t test assuming equal variance.
Error bars represent SEM.1998). Specifically, we tested whether overexpression of hppy-
RBwould modify the rough-eye phenotypes induced by expres-
sion/overexpression of EGFR pathway components using the
retinal GMR-GAL4 driver (Moses and Rubin, 1991). Expression
of UAS-hppyRB1 under the control of GMR-GAL4 had little, if
any, effect on eye morphology (compare Figures 4A and 4B).
As expected, overexpressing the EGFR using UAS-egfrWT re-
sulted in a very strong rough-eye phenotype with prominent
blistering in the dorsal anterior section of the eye (Figure 4C). A
rough-eye phenotype was also observed when expressing rlACT
under the control ofGMR-GAL4 (Figure 4E). Notably, hppy over-
expression suppressed the rough-eye and blistering phenotypes
induced by EGFR overexpression (compare Figures 4C and 4D)
but had no effect on the eye phenotype caused by expression
of rlACT (compare Figures 4E and 4F). We next asked whether
hppy overexpression would enhance the rough-eye phenotype
caused by inhibition of the EGFR pathway. We found that,
whereas expression of wild-type yan, which encodes a transcrip-
tion factor that acts downstream of rolled to inhibit the transcrip-
tion of EGFR pathway-regulated genes (Rebay and Rubin, 1995),
produced an overall normal-looking eye (Figure 4G), the
combined expression of hppy and yan underGMR-GAL4 controlproduced a severe rough and ‘‘glossy’’ eye phenotype (Fig-
ure 4H). In addition, hppy expression potently enhanced the
mild rough-eye phenotype induced by GMR-GAL4-driven
expression of UAS-egfrRNAi (Figure S7E). Thus, retinal overex-
pression of hppy ameliorated the effects of EGFR pathway over-
activation and enhanced the effects of pathway inhibition. These
data are consistent with hppy acting as an inhibitor of the EGFR
pathway. The fact that hppy overexpression did not alter the
phenotype produced by expression of rlACT suggests that
Hppy functions upstream of this MAPK.
When expressing various EGFRpathway components with the
GMR-GAL4 driver, we observed that expression of either a domi-
nant-negative form of the EGFR (UAS-egfrDN) or an activated
form of yan (UAS-yanACT) resulted in reduced viability and that
coexpression of hppy (UAS-hppyRB1) potently enhanced this
lethality (Figure 4I). These data provide evidence that hppy can
also modulate the EGFR pathway during earlier developmental
processes needed for viability and further strengthen our
hypothesis that hppy functions as an inhibitor of the pathway.
These experiments do not, however, allow us to exclude the
possibility that Hppy may function in a parallel pathway
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Figure 4. Genetic Interactions between the
EGFR Pathway and hppy
(A–H) Genetic interactions in the fly eye. GMR-
GAL4-driven hppy-RB expression suppressed
and enhanced the rough-eye phenotype caused
by overexpression of EGFR and Yan, respectively;
hppy overexpression did not affect the rough eye
of flies expressing an activated rolled transgene.
Scanning electron micrographs of adult eyes
of the following genotypes: (A) GMR-GAL4; (B)
GMR-GAL4;UAS-hppyRB1; (C) GMR-GAL4;UAS-
egfrWT, arrow points to blister; (D) GMR-GAL4;
UAS-egfrWT;UAS-hppyRB1; (E) GMR-GAL4;UAS-
rlACT; (F) GMR-GAL4;UAS-rlACT;UAS-hppyRB1;
(G) GMR-GAL4;UAS-yan; (H) GMR-GAL4;UAS-
yan;UAS-hppyRB1. Flies were heterozygous for
all transgenes. Anterior is to the right, and dorsal
is up.
(I) Genetic interactions with regard to viability.
Expression of hppy-RB enhanced the semilethality
induced by GMR-GAL4-driven expression of
a dominant-negative form of the EGFR, UAS-
egfrDN, as well as expression of an activated form
of the EGFR/ERK pathway inhibitor Yan, UAS-
yanACT. Student’s paired t test assuming equal
variance revealed a significant difference between
GMR-GAL4/+;UAS-egfrDN/+ and GMR-GAL4/+;
UAS-egfrDN/+;UAS-hppyRB1/+ (p = 0.0027) as
well as between GMR-GAL4/+;UAS-yanACT/+
and GMR-GAL4/+;UAS-yanACT/+;UAS-hppyRB1/+
(p = 0.0064) (n = 3).
(J) Genetic interactions in ethanol-induced seda-
tion. Flies expressing the RNAi transgene targeting
the EGFR, UAS-egfrRNAi, under the control of the
panneuronal driver elav-GAL4c155 in the
hppyKG5537 homozygous mutant background did
not display sensitivity to ethanol-induced seda-
tion. One-way ANOVA of ST50 values with post
hoc Newman-Keuls tests revealed a significant
difference between elav-GAL4c155;hppyKG5537/
hppyKG5537;UAS-egfrRNAi/+ and control (***p <
0.001) but failed to reveal a significant difference
between elav-GAL4c155;hppyKG5537/hppyKG5537;UAS-egfrRNAi/+ and (1) elav-GAL4c155; hppyKG5537/ hppyKG5537 (p > 0.05), (2) hppyKG5537/hppyKG5537;UAS-
egfrRNAi/+ (p > 0.05), or (3) hppyKG5537/hppyKG5537 (p > 0.05) (n = 8).
Error bars represent SEM.To determine whether hppy interacts with the EGFR pathway
in the context of ethanol-induced behaviors, we tested the
ethanol sedation sensitivity of flies expressing the UAS-egfrRNAi
transgene panneuronally in the homozygous hppyKG5537 and
hppy17-51 mutant backgrounds. In contrast to the enhanced
ethanol sensitivity seen in wild-type flies expressing the UAS-
egfrRNAi transgene panneuronally (Figure 3F), the hppyKG5537
and the hppy17-51 mutants completely suppressed this sedation
sensitivity (Figure 4J and data not shown). This finding is consis-
tent with our hypothesis that hppy functions as an inhibitor to the
EGFR pathway to regulate ethanol-induced sedation.
Acute Ethanol Exposure Leads to ERK/Rolled
Phosphorylation in hppy, but Not Wild-Type, Flies
To ask whether ethanol has an acute effect on EGFR/ERK
signaling, we examined levels of ERK (Rolled) phosphorylation
in head extracts of flies exposed to ethanol vapor as in our
behavioral assays (Figure 5A). Although ethanol did not detect-
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distinct changes were observed in hppy flies. First, basal levels
of P-ERK were substantially lower in hppy flies compared to
controls (Figure 5B). We speculate that chronic upregulation of
the EGFR/ERK pathway in hppy flies leads to compensatory
downregulation of basal P-ERK levels; similar results were
observed in brain extracts of flies in which the EGFRwas overex-
pressed panneuronally (data not shown). Second, and more
importantly, P-ERK levels were rapidly (within 5–10 min), highly,
and transiently induced by ethanol exposure in hppy, but not in
control flies (Figures 5A and 5C). This finding is consistent with
our hypothesis that hppy functions as an inhibitor of the pathway,
likely acting upstream of the ERK Rolled.
EGFR Signaling in Insulin-Producing Cells and
Dopaminergic Neurons Regulates Ethanol Sensitivity
Because panneuronal activation of the EGFR pathway resulted
in increased resistance to ethanol-induced sedation, we wished
to identify the specific cells/brain regions responsible for this
phenotype.We drove egfr overexpression using 15GAL4 drivers
whose expression patterns had been characterized previously
(Table S1). We found that overexpression of wild-type EGFR
(UAS-egfrWT) in such brain regions as the mushroom body, ellip-
soid body, or the ventral lateral neurons had no effect on ethanol-
induced sedation (Table S1). Egfr expression using a muscle
driver also produced no effect, whereas driving egfr expression
using a glial driver resulted in lethality (Table S1 and data not
shown). In contrast, strongly increased resistance to ethanol-
induced sedation was observed when driving egfr expression
in insulin-producing cells (IPCs) using the dilp2-GAL4 driver (Ru-
lifson et al., 2002) (Figure 6A) or in dopaminergic cells using the
TH-GAL4 driver (Friggi-Grelin et al., 2003) (Figure 6D). More
modest resistance was observed when overexpressing egfr
with Ddc-GAL4, which drives expression in most dopaminergic
and serotonergic neurons (Li et al., 2000) (Table S1). Importantly,
expression of GAL4 and gross morphology of cells was unaf-
fected by egfr overexpression driven by dilp2-GAL4, TH-GAL4,
or Ddc-GAL4 (compare Figures 6B and 6C, Figures 6E and F,
Figure 5. Acute Ethanol Exposure Leads to ERK Phosphorylation
in hppy, but Not Wild-Type, Flies
(A) ERK phosphorylation levels in head extracts of flies exposed to ethanol
vapor. Wild-type control and hppy flies were exposed to sedating levels of
ethanol vapor for various times as indicated. Equal levels of total brain extract
were subjected to western blot analysis using an anti diphosphoERK antibody
(top) and reprobed with an anti-ERK antibody (bottom). A representative
experiment is shown.
(B) Quantification of basal (time 0) P-ERK levels normalized to total ERK protein
levels. Basal P-ERK levels were significantly lower in hppyKG5537 compared to
control flies. p = 0.004, Student’s t test.
(C) Quantification of maximal ERK phosphorylation. P-ERK induction values
were calculated by dividing the maximal phosphorylation levels reached in
each experiment by the basal (time 0) ERK phosphorylation levels (p =
0.002, Student’s t test). The results in (B) and (C) are the mean ± SEM of
four independent experiments.and data not shown). We also expressed UAS-egfrDN with
dilp2-GAL4 and observed enhanced ethanol sensitivity (data
not shown; TH-GAL4; UAS-egfrDN flies did not survive), implying
that the EGFR pathway normally functions in these cells to regu-
late ethanol sensitivity. Thus, perturbation of the EGFR pathway
in discrete subsets of CNS neurons, but not in many others, was
sufficient to alter ethanol-induced sedation.
Pharmacological Inhibition of the EGFR in Adult Flies
Affects Ethanol-Induced Sedation
To determine whether inhibition of EGFR signaling during adult-
hood would alter ethanol sensitivity, we used the well-character-
ized EGFR inhibitor erlotinib (Tarceva). This small molecule drug
is orally bioavailable and a selective inhibitor of the tyrosine
kinase activity of the mammalian EGFR/ErbB1 (Ciardiello et al.,
2004). Adult flies were fed food containing erlotinib for 40 hr
and then tested in the ethanol LOR assay. Erlotinib-fed flies
were more sensitive to the sedating effects of ethanol compared
to vehicle-fed flies (Figures 7A and 7B). This enhanced sensitivity
did not appear to be due to abnormal ethanol pharmacokinetics,
fly feeding behavior, or ethanol-induced locomotion (Figures
S9A–S9C). A second orally active, specific, and potent inhibitor
of EGFR tyrosine kinase activity is the drug gefitinib (Iressa) (Ran-
son andWardell, 2004; Ono and Kuwano, 2006; Dutta andMaity,
2007). Similar to erlotinib, adult flies fed gefitinib exhibited
increased sensitivity to ethanol-induced sedation (Figures 7C
and 7D). These data indicate that inhibition of the EGFR pathway
during adulthood is sufficient to elicit enhanced ethanol sensi-
tivity in Drosophila. A developmental role for the pathway in
behavior is, however, also possible.
Acute Pharmacological Inhibition of EGFR Alters
Ethanol Sensitivity and Consumption in Rodents
We next asked whether acute administration of erlotinib might
alter ethanol-induced behaviors in mammals. We first deter-
mined the effects of erlotinib administration on acute ethanol
sensitivity in mice using the LOR reflex assay and found that er-
lotinib-treated mice recovered more slowly from a sedating dose
of ethanol (Figure S9D); this enhanced ethanol sensitivity is
similar to that observed in erlotinib-fed flies. We next evaluated
the effects of erlotinib on 10% ethanol and 5% sucrose
consumption in rats using the continuous-access two-bottle-
choice drinking paradigm (see Supplemental Experimental
Procedures). Once rats had achieved a stable baseline
consumption, erlotinib (5, 20, and 40 mg/kg i.p.) was adminis-
tered 30min prior to access to either ethanol or sucrose. Erlotinib
significantly decreased ethanol consumption for up to 24 hr in
a dose-dependent manner (Figure 7E). Interestingly, the effect
of the drug was selective for ethanol, as it had no effect on 5%
sucrose consumption (Figure 7F). There was no overall effect
on water consumption (Figure 7G), indicating a reduction in
ethanol preference rather than simply an alteration in overall fluid
consumption. Finally, the amount of ethanol consumed between
24 and 48 hr following erlotinib administration did not differ from
ethanol consumption after vehicle treatment (data not shown);
thus, erlotinib did not cause a rebound increase in ethanol
consumption. In summary, our data demonstrate that acute inhi-
bition of EGFR pathway signaling is sufficient to significantlyCell 137, 949–960, May 29, 2009 ª2009 Elsevier Inc. 955
Figure 6. Activation of EGFR/ERK Signaling
in Insulin-Producing Cells and Dopami-
nergic Cells Decreases Ethanol Sensitivity
as Measured in the LOR Assay
(A) Flies overexpressing a wild-type form of the
EGFR, UAS-egfrWT, in IPCs under the control of
the dilp2-GAL4 driver were resistant to ethanol-
induced sedation. A significant difference was
observed between dilp2-GAL4/+;UAS-egfrWT/+
and dilp2-GAL4/+ (**p < 0.01) as well as between
dilp2-GAL4/+;UAS-egfrWT/+ and UAS-egfrWT/+
(**p < 0.01) (n = 8).
(B and C) The projection pattern of brain IPCs ap-
peared unaffected by overexpression of EGFR.
Compare confocal images of representative adult
brains of dilp2-GAL4/+;UAS-GFP/+ flies (B) versus
dilp2-GAL4/+;UAS-GFP/+;UAS-egfrWT/+ flies (C).
(D) Flies expressing a wild-type form of the EGFR,
UAS-egfrWT, under the control of TH-GAL4 were
resistant to ethanol-induced sedation. Significant
differences were observed between TH-GAL4/+;
UAS-egfrWT/+ and (1) TH-GAL4/+ and (2) UAS-
egfrWT/+ (***p < 0.001) (n = 8).
(E and F) The projection pattern of TH-positive
dopaminergic cells in the brain appeared to be
unaffected by overexpression of EGFR. Compare
the confocal images of adult brains of TH-GAL4/+;
UAS-GFP flies (E) versus TH-GAL4/+;UAS-GFP/
+;UAS-egfrWT/+ flies (F).
(A and D) One-way ANOVA with post hoc Newman-Keuls tests.
(B, C, E, and F) Expression of GFP is green, and expression of the general neuropil marker Nc82 is purple.
Error bars represent SEM.decrease ethanol sensitivity in mice and consumption and pref-
erence in rats.
DISCUSSION
hppy Regulates Ethanol-Induced Sedation
and EGFR/ERK Signaling in Drosophila
We identified and characterized two P element mutants in the
CG7097/happyhour (hppy) gene region and found that reduced
hppy expression resulted in decreased sensitivity to ethanol-
induced sedation, whereas neuronal overexpression of hppy
caused the opposite effect. By in situ hybridization and QPCR
(data not shown), we found evidence for hppy expression in adult
brain, and behavioral rescue experiments demonstrated that
neuronal expression of hppy was sufficient to rescue the hppy
sedation resistance phenotype.
Like its mammalian homologs, the GCK-1 subfamily of Ste20
family kinases, the predicted hppy products contain N-terminal
serine/threonine kinase domains and C-terminal regulatory
domains known as citron homology domains. In vitro studies
of these homologs of Hppy, including GCK (Pombo et al.,
1995), GCK-like kinase (Diener et al., 1997), kinase homologous
to SPS1/STE20 (Tung and Blenis, 1997), and hematopoietic
progenitor kinase (HPK) (Kiefer et al., 1996), have revealed that
they activate JNK signaling, but not ERK or p38 signaling.
HPK1 (Hu et al., 1996) and GLK (Diener et al., 1997) have both
been shown to phosphorylate MAP3Ks in the JNK pathway,
implying that GCK-1 kinases are MAP4Ks acting upstream of
JNK signaling.
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MAP4K in the GCK-1 subfamily of Ste20 kinases, can modulate
EGFR/ERK signaling in a manner that is consistent with it acting
as an inhibitor of the pathway. First, retinal hppy overexpression
respectively enhanced and suppressed the rough-eye pheno-
types brought about by EGFR/ERK pathway inhibition and
activation. Second, increased hppy expression enhanced the
semilethality caused by ectopic expression of transgene EGFR
pathway inhibitors. Third, decreasing levels of hppy completely
suppressed the enhanced ethanol sensitivity brought about by
neuronal EGFR downregulation. Finally, ethanol induced robust
phosphorylation of ERK/Rolled in a hppy mutant, but not in
control flies. What, then, is the biochemical mechanism through
which Hppy inhibits EGFR/ERK signaling? The answer to this
question is still unknown. However, an in vitro study of another
GCK-1 subfamily kinase, HPK1, offers an intriguing possibility
(Anafi et al., 1997). This study showed that HPK1 physically
associates with the EGFR adaptor protein Grb2 and that EGF
stimulation recruits the Grb2/HPK1 complex to the autophos-
phorylated EGFR. This recruitment leads to the tyrosine phos-
phorylation of HPK1. It will be interesting to determine whether
such a physical association exists between Hppy and compo-
nents of the EGFR/ERK signaling cascade and, if so, what the
consequences may be on signaling.
Our experiments cannot completely rule out a role for hppy in
regulating JNK signaling, although JNK signaling perturbation
did not affect ethanol-induced sedation. In addition, hppy
mutant flies responded normally to a variety of stress stimuli
known to activate the JNK and p38 pathways, including
Figure 7. EGFR Inhibitors Alter Ethanol Sensitivity in Flies and Ethanol Consumption in Rats
(A–D) Samples of 25 flies each were fed a sucrose/yeast mixture containing either erlotinib (0.8 mg/ml; [A] and [B]) or gefitinib (0.5 mg/ml; [C and D]) dissolved in
vehicle or vehicle alone for 40 hr and were tested in the LOR assay (100 U/50 U E/A). (A and C) Sedation profiles and (B and D) ST50 values are shown. One-way
ANOVA revealed a significant difference between erlotinib- and vehicle-fed flies (p = 0.006; F1,15 = 10.341; n = 8) and between gefitinib- and vehicle-fed flies
(p = 0.022; F1,23 = 6.058; n = 12).
(E–G) Erlotinib (5–40 mg/kg i.p.) was administered to rats 30 min prior to the start of the drinking session using the continuous access to 10% ethanol or 5%
sucrose two-bottle-choice drinking paradigm (see Supplemental Experimental Procedures). Repeated-measures ANOVA followed by post hoc Newman-Keuls
analysis revealed that erlotinib significantly decreased 10% ethanol consumption (E) (p < 0.0009; F3,11 = 7.0), but not 5% sucrose consumption (F) (p > 0.05;
F3,10 = 2.0) 24 hr after onset of drinking. (G) Erlotinib treatment had no overall effect on water consumption (F3,11 = 0.6) (n = 10). Values are expressed as
mean ethanol consumed (g/kg) or mean sucrose consumed (ml).
The values are expressed as mean ethanol consumed (g/kg) ± SEM or mean sucrose consumed (ml) ± SEM. **p < 0.01 and ***p < 0.001 compared to vehicle.oxidative stress, heat stress, and starvation (data not shown).
Indeed, studies in HeLa cells show a lack of involvement of
hppy in JNK activation in response to osmotic stress and the
protein synthesis inhibitor anisomycin (Findlay et al., 2007).
The EGFR/ERK Pathway Regulates Ethanol-Induced
Sedation in Drosophila
In recent years, studies in vitro and in vivo have revealed an
intriguing link between ethanol and the mammalian EGFR/ERK
pathway, demonstrating that EGFR autophosphorylation and
ERK phosphorylation are both inhibited by pharmacologically
relevant concentrations of ethanol (Chandler and Sutton, 2005;
Ma et al., 2005). In addition, elevated expression of several
MAPKs and their regulators has been reported in the brains of
mice and rats selected for high ethanol preference (Arlinde
et al., 2004; Mulligan et al., 2006). In this paper, we uncover
a role for the EGFR/ERK pathway in mediating the behavioral
responses to ethanol in Drosophila. Neuronal manipulations
that activate the EGFR/ERK pathway resulted in enhanced resis-
tance to the sedative effects of ethanol, whereas neuronal inhibi-
tion of the pathway caused increased sensitivity. These effects
were seen upon manipulations of several different componentsof the EGFR/ERK pathway. In contrast, we found no evidence
for the other two major MAPK pathways, JNK and p38, in medi-
ating the sedative response to ethanol. Our finding that EGFR
activation specifically in either insulin-producing cells (IPCs) or
dopaminergic cells affects ethanol sensitivity is consistent with
previous studies implicating both the IPCs (Corl et al., 2005)
and dopaminergic systems (Bainton et al., 2000) in the behav-
ioral response to ethanol in Drosophila and suggests that the
EGFR/ERK pathway may interact with the insulin- and dopa-
mine-signaling pathways to control drug responses. Equally
interesting is our observation that EGFR activation in many other
brain regions, including those previously shown to play a role in
ethanol-related behaviors, such as the ellipsoid body (Urizar
et al., 2007) and the cells defined by the 201Y GAL4 line (Rodan
et al., 2002), had no effect on ethanol-induced sedation. Thus,
the EGFR pathway appears to play a role in only a subset of brain
regions that regulate flies’ response to ethanol.
The mechanisms through which the EGFR/ERK cascade
detects ethanol and how it might transduce those signals into
a behavioral response remain unknown. We found that acute
ethanol exposure, at concentrations that are behaviorally
relevant, led to a rapid and transient increase in ERK/Rolled
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phosphorylation in the heads of hppymutants, an effect that was
not observed in wild-type flies. Although this finding supports
a role for Hppy as an inhibitor of the pathway, it is unclear
whether it explains the increased resistance to ethanol-induced
sedation observed in hppy flies or in flies in which the EGFR/ERK
pathway was chronically upregulated. It is curious that our data
do not reveal an inhibitory effect of ethanol on the EGFR/ERK
pathway, as has been reported in rodents. While this may reflect
a fundamental dissimilarity in the way that the pathway operates
in flies and mammals, this discrepancy is more likely due to
the fact that mammalian experiments used chronic ethanol
exposure paradigms, whereas our experiments relied on acute
exposure.
The EGFR Regulates Ethanol Sensitivity and Preference
in Adult Flies and Rodents
We show that the EGFRhas a role in regulating ethanol behaviors
in adult flies and mammals. Administration of two well-studied
EGFR inhibitors, erlotinib (Tarceva) and gefitinib (Iressa), to adult
flies resulted in enhanced sensitivity in the LOR assay. Though
our results do not rule out a developmental role for the EGFR/
ERK pathway, they do show that this pathway can function in
the adult fly to regulate the sedative effects of ethanol. Similarly,
acute administration of erlotinib enhanced sensitivity of mice to
the sedating effects of ethanol, implying that the role of the
EGFR in this behavior is conserved among flies and rodents.
Most importantly, we found that treatment of adult rats with erlo-
tinib significantly decreased ethanol preference in a two-bottle-
choice drinking paradigm. This effect appears to be ethanol
specific, as preference for a second rewarding substrate,
sucrose, was not altered. Together, these data reveal a poten-
tially conserved role for the EGFR pathway in regulating ethanol
behaviors in both flies and rodents. Because both erlotinib (Tar-
ceva) and gefitinib (Iressa) (as well as many other small molecule
EGFR inhibitors) are FDA-approved drugs, are known to cross
the blood-brain barrier, and are well-tolerated, they offer
a possible therapeutic avenue for the treatment of AUDs in
humans.
EXPERIMENTAL PROCEDURES
Fly Genetics
Genetic Screen
Approximately 850 P[GAL4] homozygous viable strains (carrying the GawB
element) were screened in an eight-chambered locomotor tracking apparatus
at a 100 U ethanol vapor/50 U air concentration. Lines were judged to have
a mutant phenotype if they differed by at least two standard deviations from
themean at two or more consecutive time points. After retesting and extensive
backcrossing, five lines, including 17-51 (hppy), retained their mutant pheno-
types (see Supplemental Experimental Procedures for details). Flies were
raised on standard cornmeal/molasses food at 25C and 70% relative
humidity. All experiments used 2- to 5-day-old males at 20C, 25 males
per behavioral run. All genotypes were tested across multiple days. For infor-
mation about fly stocks, genetic background, and selection of control strains
see the Supplemental Experimental Procedures.
Lethality Enhancement Test
GMR-GAL4 or GMR-GAL4; UAS-hppyRB1 virgins were crossed to UAS-
yanACT/CyO or UAS-egfrDN/CyO males. Percent lethality for each genotype
was calculated as: % lethality = (1 – (# of non-Cy winged progeny / # of Cy
winged progeny)) 3 100%.
958 Cell 137, 949–960, May 29, 2009 ª2009 Elsevier Inc.Behavioral Assays
Ethanol Sedation Assay
Assays were carried out as previously described (Rothenfluh et al., 2006), with
minor modifications (see Supplemental Experimental Procedures).
Immunohistochemistry
dilp2-GAL4, TH-GAL4, Ddc-GAL4, and GAL417-51 GAL4 virgins were crossed
to UAS-GFP T2, UAS-Tau GFP males (double-transgenic stock created by
F. Wolf) or UAS-GFP T2, UAS-Tau GFP; UAS-egfrWTmales. Brains and ventral
nerve cords were dissected from adult male progeny in 1 3 PBS, fixed in 4%
paraformaldehyde for 20 min, and then washed in 13 PBS. GFP labeling was
achieved by incubating specimens in a 1:200 dilution of a rabbit anti-GFP
antibody (Clontech, Mountain View, CA) and with an FITC-coupled goat-
anti-rabbit antibody, diluted 1:500 (Molecular Probes, Eugene, OR). Neuropil
labeling was achieved by incubating specimens in a 1:10 dilution of Nc82 anti-
body (Laissue et al., 1999) and with a Cy3-coupled goat anti-mouse antibody
(1:500;Molecular Probes, Eugene, OR). Specimenswere analyzedwith a Leica
confocal microscope.
Molecular Biology
Hppy Characterization and Transgene Construction
The genomic DNA flanking the 17-51 (hppy) insertion was isolated using
inverse PCR. Comparison with the Drosophila genome sequence on Flybase
(www.flybase.org) revealed that the insertion was located 10 bp upstream of
the first exon of CG7097. This finding was confirmed by PCR analysis (data
not shown). TheUAS-hppy transgene,UAS-hppyRB, was generated by cloning
the EST RH10407, encoding full-length CG7097-RB, into the pUAST vector
(Brand and Perrimon, 1993). This transgene was injected into w Berlin flies,
and two independent insertions were obtained, UAS-hppyRB1 and UAS-
hppyRB2, yielding different levels of hppy-RB expression.
Real-Time Quantitative RT-PCR
Adult flies 2–4 days old were collected, frozen in liquid nitrogen, and then
stored at 80C. RNA was extracted from whole flies or isolated heads, as
described for each experiment, by homogenization in Trizol (Invitrogen). Quan-
titative RT-PCR was performed as described in Tsai et al. (2004). Primers and
probes recognizing CG7097-RA and CG7097-RB transcripts are described in
Supplemental Experimental Procedures.
Analysis of ERK/Rolled Phosphorylation
Twenty-five 4-day-old males of each genotype were introduced to ethanol
exposure chambers. Following 12 min of humidified air, flies were given
a continuous stream of ethanol vapor (110 U ethanol/ 40 U air) for restricted
time periods ranging from 0 to 20min and frozen immediately in liquid nitrogen.
Frozen samples were vortexed to dissociate heads from bodies. An equal
number of heads were lysed in phosphate lysis buffer (10 mM NaPO4
[pH 7.5], 5 mM EDTA, 100 mM NaCl, 1% Triton, 0.5% Na deoxycholate, and
0.1% SDS) supplemented with a mixture of protease and phosphatase
inhibitors (1 mM phenylmethylsulfonyl fluoride, 4 mg/ml aprotinin, 100 mg/ml
leupeptin, 1.5 mg/ml pepstatin A, 2 mg/ml antipain, 2 mg/ml, 10 mM NaPPi,
and phosphatase inhibitor cocktail; Sigma P2850). Equal amounts of total
head extracts were fractionated by SDS-PAGE and subjected to western
blot analysis using anti-diphosphoMAPK antibodies (Sigma M8159) and
anti-MAPK antibodies (Sigma M5670). Proteins were detected using ECL
detection reagents and autoradiography. Relative phosphorylation levels
were quantified by densitometric analysis and normalized according to protein
level.
Feeding EGFR Inhibitors to Drosophila
Flies of the genotype w Berlin were collected at 0–2 days posteclosion,
25 males per large food vial. The following day, flies were transferred to large
vials without food, each lined with a strip ofWhatman 3MMpaper and contain-
ing 1 ml of 5% sucrose, 2% yeast, and 0.02 ml of 40 mg/ml Tarceva (obtained
fromOSI Pharmaceuticals, Melville, NY) freshly dissolved in 25% cyclodextrin/
0.9% saline (vehicle); final drug concentration in food was 0.8 mg/ml. Gefitinib
feeding was carried out as for erlotinib, with 1ml of 5% sucrose, 2% yeast, and
0.01 ml of 50 mg/ml gefitinib (Biaffin GmbH & Co KG, Kassel, Germany) freshly
dissolved in DMSO (vehicle); final concentration of gefitinib was 0.5 mg/ml.
Control vials contained an equivalent volume of vehicle. Flies were returned to
a 25C incubator and kept on drug for 40–41 hr until they were assayed for
sedation.
Erlotinib Experiments in Rats
Continuous Access Two-Bottle-Choice 10% Ethanol
or 5% Sucrose Drinking Paradigm
Rats were divided into two separate groups, of which onewas trained to volun-
tarily consume 10% ethanol and the other to voluntarily consume 5% sucrose
using a two-bottle-choice drinking paradigm, as described (Steensland et al.,
2007 and Supplemental Experimental Procedures). Drug administrations
began after rats maintained stable baseline drinking levels for 2 weeks.
Drugs and Treatment Schedules
Erlotinib was generously provided by OSI Pharmaceuticals. Ethanol, sucrose,
and erlotinib solutions were prepared as described (Supplemental Experi-
mental Procedures). All rats in the erlotinib experimental groups received
each of the four treatments (vehicle, 5, 20, and 40 mg/kg), and each injection
was given 7 days apart using a Latin square design; thus, each rat served as its
own control.
Statistics
Statistical significance was established using either Student’s t tests assuming
equal variance or one-way analysis of variance (ANOVA) tests, followed by
post-hoc Newman-Keuls testing using GraphPad Prism software, Version 4
(Graphpad, San Diego, CA). Error bars in all experiments represent SEM.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight
figures, and one table and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00319-5.
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